TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Business Development

Takeda ponders exercising licensing option with Ascentage Pharma
If exercised: $100M upfront, $1.2B biobucks
Small molecule, chronic myeloid leukemia, cancer - Read more

THE GOOD
Clinical Trials

Innovent Biologics scores a 100% response rate in early Ph1 data
Bispecific antibody, lung cancer - Read more

IN8bio also goes 100% (durable remission) with allogeneic cell therapy
Allogeneic gamma-delta T cell therapy, leukemia, cancer - Read more

Vertex Pharmaceuticals provides sickle cell gene therapy 5-year follow-up data
Gene therapy, sickle cell disease, transfusion-dependent beta thalassemia - Read more

Roche is a STARGLOwing with Ph3 lymphoma results
Bispecific monoclonal antibody, diffuse large B-cell lymphoma, cancer - Read more

Cabaletta Bio’s preliminary CAR-T autoimmune data looks good, though investor’s aren’t entirely impressed
CAR-T, cell therapy, idiopathic inflammatory myopathy (IMNM), systemic lupus erythematosus (SLE) - Read more

BeiGene to showcases positive Ph3 cancer data
Small molecule, leukemia, lymphoma - Read more

THE GOOD
Fundraises

Vaxart lands BARDA funding, up to $453M
Covid-19, oral vaccine, Biomedical Advanced Research and Development Authority - Read more

Enveda Biosciences $55M raise
Small molecule, AI drug discovery - Read more

Rezolute $60M public offering
Monoclonal antibody, hypoglycemia, congenital hyperinsulinism, tumor hyperinsulinism - Read more

Sysmex Astrego awarded UK’s Longitude Prize on Antimicrobial Resistance (AMR), £8M ($10.1M)
Antibiotic resistance, urinary tract infection, point-of-care - Read more

Leo Cancer Care fundraise (amount undisclosed)
Radiation therapy, CT imaging, cancer - Read more

THE GOOD
Investments

Merck KGaA's MilliporeSigma makes a quality €62M ($66.4M) investment in new facility
Quality control, new facility - Read more

Wacker opens mRNA “competence center”, €100M ($107M)
Manufacturing, mRNA, Covid-19 vaccine - Read more

THE GOOD
IPOs

XtalPi makes Hong Kong stock exchange splash with $115M debut
AI drug discovery - Read more [Paywall]

THE GOOD
Market Reports

That’s a lot; GLP-1 market could hit $111B by 2033
GLP-1, obesity - Read more

THE GOOD
Partnerships

BioCina partners with CelluTx
CDMO, plasmids - Read more

THE GOOD
Politics & Policy

Patent reform bill could save government $3B over a decade
Pharma patents, product hopping - Read more [Paywall]

THE GOOD
Regulatory

FDA, Health Canada, and the UK’s Medicines and Healthcare products Regulatory Agency push for greater AI transparency - Read more

FDA pivots, says Covid-19 vaccine developers should focus on KP.2 strain
Covid-19 vaccine update - Read more

THE GOOD
Strategic Plans

enGene zeroes in on bladder cancer (by dropping their preclinical cystic fibrosis program)
Nanoparticle, non-viral plasmid DNA, bladder cancer - Read more

THE BAD
Clinical Trials

Kyverna Therapeutics drops new autoimmune CAR-T data with some concerning data points
CAR-T, cell therapy, lupus nephritis - Read more 

THE BAD
IPOs

Telix Pharmaceuticals ditches IPO due to “market conditions”
Radiopharma, radio antibody-drug conjudgate, prostrate cancer - Read more

THE BAD
Partnerships

BeiGene and NewBridge Pharmaceuticals part partnership ways
Small molecule, cancer, lymphoma, leukemia - Read more

THE BAD
Patient Access

Michigan’s Blue Cross Blue Shield rolls back GLP-1 coverage due to rising costs
GLP-1, insurance coverage, obesity, weight loss - Read more

THE BAD
Politics & Policy

FDA’s rare pediatric disease voucher program has an uncertain future
Rare disease, pediatric, FDA voucher - Read more [Paywall]

THE BAD
Regulatory

FDA’s adcomm structure comes under patient fire
Advisory committee, patient feedback - Read more

THE UGLY
Clinical Trials

Gilead made a terrible $4.9B bet by acquiring Forty Seven
Monoclonal antibody, myelodysplastic syndrome - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 350+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.